Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott J. Rodig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Scott Rodig and Geoffrey Shapiro.
Connection Strength

1.628
  1. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010 Dec; 11(12):1477-90.
    View in: PubMed
    Score: 0.471
  2. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep. 2016 11 22; 17(9):2367-2381.
    View in: PubMed
    Score: 0.178
  3. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012 Sep 15; 18(18):4973-85.
    View in: PubMed
    Score: 0.132
  4. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):370-80.
    View in: PubMed
    Score: 0.131
  5. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607.
    View in: PubMed
    Score: 0.128
  6. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med. 2011 Jun 26; 17(7):875-82.
    View in: PubMed
    Score: 0.122
  7. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010 Oct 28; 363(18):1727-33.
    View in: PubMed
    Score: 0.117
  8. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 Jan; 2(1):66-82.
    View in: PubMed
    Score: 0.059
  9. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543.
    View in: PubMed
    Score: 0.057
  10. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459.
    View in: PubMed
    Score: 0.056
  11. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290.
    View in: PubMed
    Score: 0.046
  12. Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):323-6; quiz 326.
    View in: PubMed
    Score: 0.037
  13. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec; 3(12):1355-63.
    View in: PubMed
    Score: 0.036
  14. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010 Dec 15; 70(24):10038-43.
    View in: PubMed
    Score: 0.029
  15. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010 Dec 01; 70(23):9827-36.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.